Obesity predisposes to human type 2 diabetes, the most common cause of diabetic retinopathy. To determine if high-fat diet–induced diabetes in mice can model retinal disease, we weaned mice to chow or a high-fat diet and tested the hypothesis that diet-induced metabolic disease promotes retinopathy. Compared with controls, mice fed a diet providing 42% of energy as fat developed obesity-related glucose intolerance by 6 months. There was no evidence of microvascular disease until 12 months, when trypsin digests and dye leakage assays showed high fat–fed mice had greater atrophic capillaries, pericyte ghosts, and permeability than controls. However, electroretinographic dysfunction began at 6 months in high fat–fed mice, manifested by increased latencies and reduced amplitudes of oscillatory potentials compared with controls. These electroretinographic abnormalities were correlated with glucose intolerance. Unexpectedly, retinas from high fat–fed mice manifested striking induction of stress kinase and neural inflamasome activation at 3 months, before the development of systemic glucose intolerance, electroretinographic defects, or microvascular disease. These results suggest that retinal disease in the diabetic milieu may progress through inflammatory and neuroretinal stages long before the development of vascular lesions representing the classic hallmark of diabetic retinopathy, establishing a model for assessing novel interventions to treat eye disease.

Despite new approaches, diabetic retinopathy (DR) continues to ravage vision (1). Vascular endothelial growth factor (VEGF) plays a definitive role in the disease, and its antagonism with neutralizing molecules represents an authentic advance in diabetes care (2,3). Yet, in practice and in clinical trials, anti-VEGF agents are not always efficacious, require frequent administration, and may have adverse effects (4). VEGF antagonism in mice may disrupt long-term visual function (5). Other therapies are destructive or are associated with serious adverse effects (6). The growing rate of diabetic visual complications represents an unmet need. The development of novel treatments is limited by a surprising lack of relevant models for retinopathy in obesity-related type 2 diabetes and an incomplete understanding of the sequential evolution of the disease.

Rodent models of DR can be simplified into those that are spontaneous due to genetic background (including the db/db and Ins2Akita mice and the ZDF and GK rats) (7,8) and those that require induction, such as models using the β-cell toxin streptozotocin (STZ) (9). STZ can be used in disease-free animals and acts quickly. A disadvantage is that this drug is a potent alkylating agent, with off-target effects that include immunosuppression (10) and toxicity to the kidney (11), liver (12), and brain (13–15). Sometimes considered to model human type 1 diabetes, mice given STZ fail to reproduce key features of the disease. Notably, humans with type 1 diabetes die without insulin; STZ-treated mice do not require insulin for survival.

Compared with the STZ-administered mouse, the Ins2Akita mouse is more reflective of the physiology of type 1 diabetes. However, this model is the subject of variable reports regarding eye phenotypes, ranging from mild changes (16) to advanced abnormalities that include neovascular features (7,17). The widely used rodent type 2
diabetes model, db/db, is caused by a leptin-receptor mutation. However, leptin signaling affects the retina (18), suggesting that these animals are not an ideal model for obesity-related DR.

A high-fat diet (HFD) promotes obesity, insulin resistance, and diabetes in rodents (19). Curiously, although some studies have used HFDs to study eye disease, we are unaware of any linking HFD-induced diabetes to retinal microvascular disease. We studied retinal structure and function over time to determine if diabetes induced by feeding without administration of a potential neurotoxin could model retinal disease in mice. Our findings show that HFD feeding produces retinopathy characterized by sequential inflammation, neurologic dysfunction, and then vascular dysfunction.

**RESEARCH DESIGN AND METHODS**

**Animals**

Protocols followed the Association for Research in Vision and Ophthalmology Statement for the Use of Animals and were approved by Washington University in St. Louis. C57BL/6J mice were free of RD1 or RD8 mutations. Animals were weaned onto Purina 4043 chow (13% kcal from fat, 42% kcal from carbohydrate, and 15% kcal from protein) or Harlan Teklad TD 88137 HFD (42% kcal from fat, 43% kcal from carbohydrate, and 15% kcal from protein).

**Antibodies and PCR Primers**

For Western blotting, we used monoclonal rat IgG against mouse NACHT, LRR, and PYD domain-containing protein (NALP3, encoded by the Nlrp3 gene and also referred to as pyrin domain-containing protein 3 [NLRP3]) (cat. no. MAB7578, R&D Systems, Minneapolis, MN), polyclonal goat IgG against mouse interleukin (IL)-1β (cat. no. AF-401-NA, R&D Systems), polyclonal rabbit IgG against mouse caspase-1 p10 (M20) subunit (cat. no. sc-514, Santa Cruz Biotechnology, Dallas, TX), polyclonal rabbit IgG against phosphorylated Thr183/Thr185 c-Jun N-terminal kinase (JNK) (cat. no. 9251, Cell Signaling Technology, Beverly, MA), and polyclonal rabbit IgG against JNK/stress activated protein kinase (cat. no. 9252, Cell Signaling Technology). For immunostaining, anti-NALP3 was used at 1:100, anti-adaptor protein apoptosis-associated-speck-like protein containing CARD (ASC) (cat. no. AL177, Adipogen Corporation, San Diego, CA) was used at 1:200, and anti-Iba1 (cat. no. 019-19741, Wako, Richmond, VA) was used at 1:400. PCR primers were as follows:

**Vegf-a:** sense 5’-AATGCTTTCTCCGCTCTGAA-3’, antisense 5’-GCTTCTACACGACGACGAGA-3’

**Icam-1:** sense 5’-AACATTACCTCGACGAGGAC-3’, antisense 5’-GTCCCTCTTGATCCCTG-3’

**Gfap:** sense 5’-TTTCTTGATCTTGGGATTTG-3’, antisense 5’-AGATGCCAATTCCAGGAA-3’

**Gapdh:** sense 5’-TGACCCCAACTGGTCTACC-3’, antisense 5’-GGCATGACTGTGGTCATGA-3’

**β-actin:** sense 5’-TCCATCATGAAGTGTGACGT-3’, antisense 5’-GAGCAATGATCTTGATCTCAT-3’

**Rpl32:** sense 5’-GGCTTTGCCTTLAGGAGA-3’, antisense 5’-TTCTGGTCACATGCTGCAAA-3’

Gene expression data were normalized to the mean of Gapdh, β-actin, and ribosomal protein L32.

**Metabolic Parameters**

Body composition was assessed by MRI (3-in-1 instrument; EchoMRI, Houston, TX). Glucose and insulin tolerance tests were performed after a 6-h fast in animals housed with hardwood bedding and treated intraperitoneally with 1 g/kg dextrose or 0.75 units/kg regular human insulin. Glucose was measured 10, 30, 60, and 120 min later.

**Retinal Morphologic Assay**

Eyes from male and female mice were fixed in 4% paraformaldehyde at 4°C for 48 h, embedded in paraffin, sectioned into 4-μm slices, and stained with hematoxylin and eosin. For trypsin digests, isolated retinas were washed overnight with distilled water at 37°C and then incubated with 1% porcine trypsin in 1 mol/L Tris-EDTA buffer (pH 7.5) for 3 h. Neuroglial elements were washed away by dripping tap water at 25°C. Remaining vascular skeletons were air dried, incubated with 10% formalin at 25°C for 10 min, stained with periodic acid Schiff base and hematoxylin, and then mounted.

**Vascular Permeability Assays**

Under anesthesia, Evans Blue (EB) dye (25 mg/kg of 1% solution) was injected into the left iliac vein with a 32-gauge needle and allowed to circulate for 180 min. Mice were killed, and whole blood was removed from the left ventricle with a 29-gauge needle. Plasma was isolated at 10,000 g for 10 min with removal of 10 μL of the supernatant, which was diluted 1:100 in formamide. From enucleated globes, 3 μL of aqueous fluid was removed from the anterior chamber with a 10-μL capacity Hamilton syringe and diluted into 97 μL of formamide. Samples were incubated in formamide at room temperature overnight. EB absorbance was determined by subtracting absorbance at 740 nm from that at 620 nm. The results were generated by comparison with a standard curve, normalized to the plasma concentration, and expressed as ratios between aqueous solution and plasma. Retinas were then isolated from remaining fixed globes, flat mounted, and imaged with a Leica DMi4000B inverted fluorescence microscope. Fluorescein angiography was performed by administering sodium fluorescein (5 mg/kg of 10% w/v; cat. no. 17478-253-10, Akorn, Lake Forest, IL) to anesthetized 6- or 12-month-old animals. Fundus photographs were obtained 2 min later with a Micron III camera (Phoenix, Pleasanton, CA).

**Electroretinography**

A UTAS BigShot System (LKC Technologies, Inc., Gaithersburg, MD) was used. Mice (≥5 for each group) were dark adapted.
overnight. Under red light illumination, animals were anesthetized with ketamine (80 mg/kg total body mass) and xylazine (15 mg/kg lean body mass). Pupils were dilated with 1% atropine sulfate. Body temperature was maintained at 37°C with a heating pad. Contact lens electrodes were placed bilaterally with appropriate reference and ground electrodes.

The stimulus consisted of a full-field white light flash (10 µs) in darkness or in the presence of dim (30.0 candela [cd]/m²) background illumination after 10 min adaptation time. The response was recorded over 231 ms plus 25 ms of pretrial baseline. Between 5 and 10 repeated trials were averaged for each luminance, with 10 repeats used for the dimmest flashes, and 5 for the brightest. Raw data were processed using MATLAB software (MathWorks, Natick, MA). The amplitude of the a-wave was measured from the average pretrial baseline to the most negative point of the average trace, and the b-wave amplitude was measured from that point to the highest positive point, after subtracting oscillatory potentials (OPs). The eye with the larger recorded b-wave amplitude was used for each mouse. OPs were isolated using a digital Butterworth 25 Hz high-pass filter and quantified using root-mean-square analysis of filtered waves, normalized to the maximal b-wave amplitude. The log luminance of the stimulus (log [cd · s/m²]) was calculated based on the manufacturer’s calibrations.

Statistical Analysis
Distributions of electroretinography (ERG) responses across diet groups at different light intensities are described by means ± SEM. Differences were compared using two-way ANOVA, followed by a Bonferroni post hoc test for multiple comparisons.

RESULTS
HFD Feeding Produces a Type 2 Diabetes Phenotype
HFD feeding accelerates weight gain and adiposity (19). Significant gains in total weight in mice fed the HFD compared with controls were measured at 6 months. This difference progressed through 12 months of age (Fig. 1A). Nearly all of the weight difference between mice on chow and the HFD was due to increased adiposity (Fig. 1B and C). Animals fed the HFD developed abnormal glucose metabolism by 6 months of age that persisted through 12 months of age, as assessed by glucose tolerance tests (Fig. 1D–G) and insulin tolerance tests (Fig. 1H).

Animals fed the HFD developed hyperinsulinemia that peaked at 6 months of age and was less marked by 12 months (Fig. 1I). Consistent with other models of HFD-induced obesity, this pattern likely reflects initial β-cell hypersecretion, followed by β-cell dysfunction and loss mirroring the progression of human type 2 diabetes.

Gross Retinal Morphology Is Preserved After Prolonged HFD-Induced Diabetes
STZ induces thinning of the inner retina as soon as 2 months after diabetes induction (20). To determine if HFD-induced diabetes promotes inner retinal cell loss, we compared cross-sectional retinal thickness between chow-fed and HFD-fed mice at 12 months of age. As shown in Fig. 2A and B, there were no apparent changes in total retinal thickness or in the thickness of any individual retinal laminae. In the juxtapapillary retina, maximal total thickness was 235.6 ± 66.3 μm (mean ± SD) in the chow group and 229.9 ± 70.9 μm in the HFD group (P > 0.99). Maximal juxtapapillary inner nuclear layer thickness was 34.8 ± 10.4 μm in the chow group and 30.5 ± 13.2 μm in the HFD group (P > 0.99). These retinal layers were quantified at various distances from the optic nerve in dorsal (negative distances) and ventral (positive distances) directions, as shown in Fig. 2C and D. There were no differences in any of the major retinal laminae maximal thicknesses, including the retinal ganglion cell layer (12.0 ± 5.1 μm chow vs. 11.5 ± 3.7 μm HFD, P > 0.99), the inner plexiform layer (54.6 ± 21.2 μm chow vs. 48.2 ± 9.6 μm HFD, P > 0.99), the outer plexiform layer (15.8 ± 6.0 μm chow vs. 16.0 ± 5.5 μm HFD, P > 0.99), or the outer nuclear layer (59.3 ± 17.2 μm chow vs. 55.4 ± 21.2 μm HFD, P > 0.99). These results differ from those obtained with animals given STZ but are consistent with human data showing no thinning of the inner nuclear retina in early diabetes (21,22). Therefore, the HFD-fed mouse may model human DR in its early stages, when interventions are likely to provide benefit, with greater fidelity than in the mouse given STZ.

Time-Dependent Retinal Vascular Damage Is Associated With HFD-Induced Diabetes
Vascular stigmata of human nonproliferative DR that are visible by ophthalmoscopy, such as microaneurysms, dot-blot hemorrhages, venous beading, and intraretinal microvascular anomalies, are absent in most rodent retinopathy models. Histopathologic features, such as capillary basement membrane thickening, loss of pericytes, and atrophy of small capillaries, are present in diabetic animals (23). To determine whether animals fed an HFD develop vascular lesions typical of rodent diabetes models, we analyzed trypsin-digested skeletons of microvessels. Digested retinas from chow- or HFD-fed animals were flat mounted and stained as shown in Fig. 3A. A masked observer scored the number of atrophic capillaries or pericyte ghosts per high-power field (Fig. 3B). There were no differences in the mean number of atrophic capillaries or pericyte ghosts between HFD-fed animals and chow-fed controls at 6 months of age (Fig. 3C and D). At 12 months of age, however, HFD animals showed more atrophic capillaries (P < 0.001) and pericyte ghosts (P < 0.01) compared with controls.
Permeability of Retinal Vessels Is Increased by HFD Feeding

The EB dye normally stays within the plasma compartment for hours. In experimental diabetes, abnormal EB leakage is readily detected in the neural retina and vitreous (24). To determine whether HFD-fed animals develop disruptions in the blood-retina barrier (BRB) characteristic of DR, we used a modified EB dye leakage assay. At 3 h after dye circulation, we determined BRB disruption by the presence of blue color within the anterior chamber of enucleated globes and in flat-mounted retinas. As shown in Fig. 4A, the anterior chambers of 12-month-old animals fed the HFD were bluer than those of age-matched chow-fed controls after an identical period of dye circulation. Retinal flat mounts from HFD-fed or chow-fed animals demonstrated distinctive dye patterns using fluorescence microscopy. In chow-fed animals, EB was mostly detected in the microvascular space with discrete patterns of fluorescence (Fig. 4B and D). In older animals fed the HFD, we detected a more diffuse, “ground-glass” background fluorescence indicative of EB leakage (Fig. 4C and E). HFD-fed animals had more EB leakage into the aqueous compartment than controls at 12 months ($P < 0.05$) but not 6 months (Fig. 4F). An independent technique, fluorescein angiography, showed patterns consistent with increased leakage in HFD-fed mice compared with chow-fed controls in 12-month-old animals (Supplementary Fig. 1), suggesting vascular leakage in vivo with HFD feeding. Dye leakage at 12 months in HFD-fed animals coincided with elevations in typical markers of retinal endothelial damage and gliosis, consistent with other models of DR (Fig. 4G–I).
HFD Feeding Promotes Retinal Neural Dysfunction

Although the hallmark of DR is vascular disease, antecedent or coincident neural deficits also occur in humans (25–28). Whether neural effects are involved in the etiology of DR in rodents is less clear. To determine whether neurologic dysfunction occurs early in HFD-induced DR, we performed full-field, stimulus-evoked scotopic and photopic ERGs in HFD-fed mice and chow-fed controls.

After dark adaption overnight, scotopic ERG was performed with full-field white stimuli given across increasing intensities. Thereafter, a 10-min period of light adaptation was performed against a dim white background of 30-cd/m² luminance. Photopic ERG was recorded at increasing stimulus intensities. Raw ERG data were then analyzed for a-wave (scotopic reading only) and b-wave (in both scotopic and photopic conditions) amplitudes and implicit times. The raw waves were processed through a digital high-pass filter to isolate early OPs, as shown in Fig. 5A.

As expected, maximal ERG responses to white light stimuli for both a-waves (Fig. 5B, D, and F) and b-waves (Fig. 5C, E, and G) declined with age. At no age did we observe a difference in amplitudes or implicit times in scotopic a-waves or b-waves between HFD and control groups. There were no differences in photopic b-wave characteristics between different groups at any age (data not shown). Amplitudes of summed OPs did not differ between dietary groups at 3 or 6 months of age (Fig. 6A and B). However, at 12 months of age, average OP amplitudes were significantly reduced in HFD-fed animals compared with chow-fed controls at all stimulus intensities (P < 0.05) except for the dimmest (−2.4 log [cd · s/m²]) and brightest (0.89 log [cd · s/m²]). Examples of the preferential decline in OP amplitudes in HFD-fed animals compared with controls, with relative preservation of a-wave and b-wave amplitudes, are shown in Fig. 6G.

HFD feeding promotes insulin resistance (Fig. 1), but individual mice show variable glucose tolerance responses. To determine whether mice with greater glucose intolerance (i.e., higher area under the curve [AUC] values during a glucose tolerance test [GTT]) also have a greater reduction in OP amplitudes, we correlated OP amplitudes with...
AUC of the GTT for individual mice at different ages. At 3 months (Fig. 6D), no correlation was found between glucose tolerance and OP amplitudes in either dietary group. However, at 6 months (Fig. 6E), the AUC of the GTT was correlated with lower OP amplitudes in the HFD-group ($R^2 = 0.60$, $P = 0.04$). In contrast, no such correlation was found for chow-fed animals of the same age ($R^2 = 0.02$, $P = 0.81$). At 12 months (Fig. 6F), the correlation between glucose tolerance and lower OP amplitudes was also present in HFD animals ($R^2 = 0.51$, $P = 0.009$) but not in chow-fed controls ($R^2 = 0.12$, $P = 0.5$).

Prompted by this correlation, we determined whether OP kinetics may be affected in the HFD-induced diabetes model by measuring the latency time for each of the first four OPs recorded on scotopic ERG at 3, 6, and 12 months (Fig. 7). Beginning at 6 months of age, a significant delay in implicit time for the first two OPs (OP1 and OP2) elicited by a $-0.60 \log (cd \cdot s/m^2)$ white light flash was observed in HFD-fed animals ($27.1 \pm 2.2$ ms) compared with controls ($24.3 \pm 1.8$ ms) at OP1 ($P < 0.05$). This delay persisted through 12 months, with an average OP1 implicit time of $25.6 \pm 2.0$ ms in HFD-fed animals compared with $24.2 \pm 1.4$ ms in chow-fed controls ($P < 0.05$) and an average OP2 implicit time of $32.0 \pm 2.6$ ms in HFD-fed animals compared with $30.5 \pm 1.9$ ms in chow-fed controls ($P < 0.05$). These data are consistent with the notion that diet-induced insulin resistance promotes early neurologic deficits in the retina. By ERG analysis, these deficits are manifested as reductions in amplitude and delays in OP responses to white light stimuli under scotopic conditions. Thus, electrophysiologic abnormalities detected at 6 months precede the development of vascular abnormalities at 12 months (Figs. 3 and 4) in a diabetes model induced by a clinically relevant diet without genetic manipulations or administration of toxins.

To investigate potential mechanisms responsible for these ERG defects, we examined retinal expression of factors known to be altered in metabolic disease. NLRP3 is an important regulator of cellular responses to obesity-relates diabetes (29). NLRP3 inflammasomes, classically

Figure 3—At an advanced age, HFD-fed mice develop typical lesions of DR. Retinal vasculature networks were analyzed in 6- and 12-month-old animals by trypsin digest of isolated and fixed retinas, followed by periodic acid Schiff/hematoxylin staining. A: Representative example, under low-power magnification, of a trypsin-digested and stained retina. Grading of vascular lesions was performed under high-power magnification in the midperipheral retina at standardized areas across all samples, as indicated by the black boxes. B: Shown are examples of healthy-appearing pericytes (top three panels, arrowheads) or typical examples of vascular pathologies, including pericyte ghosts (middle three panels, arrows) and atrophic capillaries (bottom panels). Scale bar = 25 μm. HFD-fed animals develop significantly more atrophic capillaries (C) and pericyte ghosts (D) at 12 months, but not 6 months, of age, compared with chow-fed controls. Shown are quantities of vascular lesions, as assessed by a masked grader. Values represent mean ± SEM from 10 independent experiments in each group. **$P < 0.01$, ***$P < 0.001$ by ANOVA.
thought to direct immune responses against infectious agents, also respond to sterile damage-associated molecular patterns. These include oxidative stressors derived from excess fatty acids and glucose in diabetes (30,31). The HFD, compared with chow, robustly increased NLRP3 protein in the retina at 3 months, before the development of neural or vascular defects, an effect that persisted at 6 and 12 months (Fig. 8A and B). The cleaved, active forms of the NLRP3-dependent effectors IL-1β (mature IL-1β, 17 kDa) and caspase-1 (10 kDa) were increased in retinas...
Figure 5—HFD feeding does not alter major retinal responses to light stimuli. ERG responses were recorded from animals in scotopic conditions after overnight dark adaptation. A: A high-pass filter was applied to the raw ERG to isolate the OPs for separate analysis from the a-wave and b-wave measurements. ERG a-wave amplitudes recorded at 3, 6, and 12 months of age are plotted against stimulus luminance (B, D, and F), with corresponding b-wave amplitudes (C, E, and G). Values represent the mean ± SEM from at least five animals at each age. Decline in amplitudes of responses are seen with increasing age. At all tested ages, no significant differences were observed between animals on different diets with regard to either major ERG component (ANOVA).
from HFD-fed but not chow-fed animals at all time points (Fig. 8A, C, and D). Phosphorylated JNK, an important stress signal in diabetes, was increased in HFD compared with control retinas (Fig. 8E).

Inflammation activity contributes to retinal disease (30,32,33), with retinal induction of NLRP3 thought to occur in endothelium or macrophages. Imaging of NLRP3 and its adaptor protein ASC unexpectedly demonstrated colocalization of these inflammatory mediators in the inner nuclear and ganglion cell layers (Fig. 8F). These signals predominantly occur within cell bodies of ganglion cells and inner nuclear cells (Fig. 8F) rather than in vascular tissues. Stress signaling in this context likely reflects a chronic inflammatory change affecting multiple cell types. Consistent with this scenario, increased Iba1, reflecting microglial activation, was detected in HFD-fed mice compared with controls at 12 months (Supplementary Fig. 2). This signal was found in the deeper portions of the inner

Figure 6—Aged HFD-fed mice have decreased OP amplitudes compared with controls. Visual function in HFD- or chow-fed animals was assessed at 3, 6, and 12 months of age by ERG under scotopic, dark-adapted conditions. OPs were extracted from the raw ERG trace using a high-pass filter. The root mean square (RMS) of all OP peaks and troughs were normalized to the amplitude of the maximal b wave. RMS of OP amplitudes are plotted against stimulus luminance at 3 (A), 6 (B), and 12 (C) months of age. At 12 months of age, mice fed the HFD demonstrate significant declines in OP amplitudes relative to controls. Values represent the mean ± SEM from at least five animals at each age. *P < 0.05 by ANOVA. D–F: Reductions in OP amplitudes correlate with glucose intolerance beginning at 6 months of age. Correlation plots of normalized OP amplitude with the AUC for the intraperitoneal GTT are shown for animals at 3 (D), 6 (E), and 12 (F) months of age. Each data point represents a unique animal. Pearson correlation analyses were performed for animals fed each diet at each tested age, with R² and P values shown in the lower right corner of each graph. G: Representative ERG tracings from mice fed each of the two indicated diets, with the HFD-fed mice displaying reductions in OP amplitudes compared with chow-fed controls.
plexiform layer, distinct from ganglion cell bodies. These results suggest that HFD feeding induces a chronic inflammatory program that includes stress signaling in the inner retina, at least in part due to NLRP3 activity and JNK kinase activation, before the development of ERG and vascular defects. The temporal sequence of inflammatory activation, systemic glucose intolerance, ERG deficits, and vascular abnormalities in our mouse model suggests that HFD-initiated retinal stress signaling contributes to diabetes-related eye disease.

DISCUSSION

DR affects blood vessels. In humans and mice, the earliest visible signs of the disease are vascular. Yet, neurologic activity in the retina is metabolically demanding (34), raising the possibility that retinal neural function might be deranged in the setting of diabetes. If so, early neural insults could be related to vascular damage in the retina. In the current work, we provide evidence that retinal function is compromised in diet-induced diabetes in mice before the development of detectable defects in the retinal vasculature.

Using a clinically relevant diet, we show that the development of obesity, glucose intolerance, and insulin resistance in mice is associated with microvascular atrophy and pericyte damage by 1 year of age. Using ERG, we show that a functional neurologic deficit occurs by 6 months, before vascular injury. This functional abnormality persists to 12 months and is correlated with glucose intolerance, consistent with a temporal relationship linking metabolism, neural dysfunction, and the eventual development of microvascular disease. We also provide evidence that aberrant stress signaling induced by the HFD precedes ERG and retinal microvascular defects.

The relationship between early ERG dysfunction and retinopathy development is less clear in other mouse models. In the db/db mouse, which develops a disease similar to type 2 diabetes due to leptin receptor deficiency, massive reductions in b-wave amplitude have been recorded at ~6 months of age (35). These findings coincide with vascular defects, including morphological abnormalities and abnormal leakage. However, leptin signaling has important trophic and angiogenic effects in the retina that may account for the ERG deficits seen in these mice (18). In the STZ diabetes model, ERG and structural vascular abnormalities have both been identified (36–38), but STZ causes off-target neurologic effects (14,15). Moreover, STZ causes rapid onset of severe disease that would obscure a potential early neural contribution. Retinal inflammation and degeneration were recently demonstrated in diet-induced metabolic disease in rodents (39,40). A new rat model of type 2 diabetes manifests features of retinal inflammation and vascular disease coincident with severe metabolic derangements (41). These newer studies did not report ERG responses.

The current HFD-fed model is characterized by slow-onset disease, mirroring the pathophysiology of human type 2 diabetes complications such as retinopathy. Even after 1 year of age, HFD mice do not lose inner retinal thickness, confirming that the disease in these animals is mild and similar to what is seen in early human retinopathy (21,22). Our findings that OP disruptions precede the appearance of vascular disease are consistent with data from humans, where electrophysiology is impaired before visible microvascular disease, with clinical impairment frequently involving these same waveforms (26,28,42).

Our ERG changes are small but exquisitely specific to OPs. Unlike the catastrophic ERG effects caused by mutations in visual cycle proteins, ERG deficits in diabetes models are expected to be modest. Rodent full-field ERG represents a summed response of the neural retina to light. However, as in human DR, experimentally induced DR is not expected to be uniform. In humans, multifocal...
ERG identifies preferentially affected regions that subsequently develop classic vascular lesions of retinopathy (43,44). Analogous multifocal recording capability is not available in rodents. Structural and functional assays of blood vessel integrity offer greater spatial resolution compared with visual function assays. Given the low resolution of full-field ERG in mice, it is striking that functional deficits correlated with glucose intolerance precede the detection of vascular defects. OP characteristics can lead to artifacts in b-wave recordings (45,46), but no b-wave changes between groups were detected.

Altered OPs likely reflect perturbations of the inner retina, specifically dysfunctional amacrine, bipolar, and retinal ganglion cells (47,48). Many studies during the past half century have reported decreased OP amplitude as the earliest sign of DR (26,28,42). Consistent with these observations, our findings suggest that inner retinal networks may be important early targets of disease. Alternatively, early ERG dysfunction in humans and mice could be caused by microvascular disease that cannot be detected with current technologies. Another possibility is that diet-induced diabetes perturbs neuroglial-vascular coupling mediated by arachidonic acid metabolites, nitric oxide, semaphorin 3a, and VEGF, all affected by diabetes (49–52).

Inflammation (NLRP3, cleaved IL-1β, cleaved caspase-1, phosphorylated JNK, and ASC recruitment) was induced in the inner retina by the HFD before the development...
of OP abnormalities or detectable vascular disease. Obesity-related diabetes promotes inflammation, and our work demonstrated this effect in the retina. Possible priming mechanisms contributing to inflammation activation include delivery of fatty acids (29,53), altered de novo lipogenesis (54), or disrupted redox chemistry (31). Our current findings are only associative. Additional studies will be required to define HFD-induced relationships between cellular effectors. But this work links inflammatory activation in a temporal sequence leading to ocular defects, providing rationale for manipulating the inflammasome to treat retinopathy.

In short, the HFD-fed mouse model could be useful for studying early neuronal, glial, or neurovascular dysfunction underlying retinal disease in type 2 diabetes. Identifying novel targets or biomarkers in this model could facilitate the development of disease-modifying therapies for this devastating cause of blindness.

Acknowledgments. The authors thank Dr. Rajendra Apte, Dr. Sene Abdoulaye, and Andrea Santerford (Washington University School of Medicine) for antibodies against Iba1 and for assistance with angiography experiments. The authors also thank Dr. Fumihiko Urano and Dr. Babak Razani (Washington University of Medicine) for valuable reagents to detect inflammatory components. The authors are grateful for the technical assistance provided by Belinda McMahan (Washington University School of Medicine).

Funding. This work was supported by National Institutes of Health grants DK-101392, DK-076729, DK-020579, DK-056341, and P30-EY-002687 and an unrestricted grant to the Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. R.R. designed experiments, researched data, and wrote the manuscript. G.W.B., S.Z., and L.Y. researched data and edited the manuscript. F.L. contributed to the experimental design and edited the manuscript. C.F.S. designed experiments and wrote the manuscript. R.R. is the guarantor of this work, and, as such, had full access to all the data in the manuscript. C.F.S. designed experiments and wrote the manuscript. R.R. designed experiments, researched data, and wrote the manuscript. G.W.B., S.Z., and L.Y. researched data and edited the manuscript. P.L. contributed to the experimental design and edited the manuscript. C.F.S. designed experiments and wrote the manuscript. R.R. is the guarantor of this work, and, as such, had full access to all the data in the manuscript. C.F.S. designed experiments and wrote the manuscript. P.L. contributed to the experimental design and edited the manuscript. C.F.S. designed experiments and wrote the manuscript. R.R. is the guarantor of this work, and, as such, had full access to all the data in the manuscript. C.F.S. designed experiments and wrote the manuscript. R.R. is the guarantor of this work, and, as such, had full access to all the data in the manuscript. C.F.S. designed experiments and wrote the manuscript. P.L. contributed to the experimental design and edited the manuscript. C.F.S. designed experiments and wrote the manuscript.

Prior Presentation. Parts of this study were presented in abstract form at the Association for Research in Vision Annual Meeting, Denver, CO, 3–7 May 2015.

References
1. World Health Organization. Prevention of Blindness and Visual Impairment. Global Data on Visual Impairments 2010 [article online]. Available from http://www.who.int/blindness/publications/globaldata/en/. Accessed 14 March 2014
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487
3. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antibody bridging fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859–870
4. Do DV, Nguyen QD, Khwaja AA, et al.; READ-2 Study Group. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013;131:139–145
5. Kurilta H, Westenskov PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 2012;122:4213–4217
6. Gillies MC, McAllister IL, Zhu M, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology 2011;118:866–872
7. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005;46:2210–2218
8. Midenia E, Segato T, Radin S, et al. Studies on the retina of the diabetic db/db mouse. I. Endothelial cell-pericyte ratio. Ophthalmic Res 1989;21:106–111
9. Babel J, Leuenberger P. A long term study on the ocular lesions in streptozotocin diabetic rats. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1974;189:191–209
10. Muller YM, Golshayan D, Ehrichou D, et al. Immunosuppressive effects of streptozotocin-induced diabetes result in absolute lymphopenia and a relative increase of T regulatory cells. Diabetes 2011;60:2331–2340
11. Perry DJ, Weiss RB. Nephroprotective effects of streptozotocin. Ann Intern Med 1982;96:122
12. Kume E, Fujimura H, Matsuki N, et al. Hepatic changes in the acute phase of streptozotocin (SZ)-induced diabetes in mice. Exp Toxicol Pathol 2004;55:467–480
13. Krasa K, Sanit MD, Dorieux O, et al. In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. PLoS One 2012;7:e46196
14. Rai S, Kamat PK, Nath C, Shukla R. Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav 2014;117:104–117
15. Shoham S, Bejar C, Kovalov E, Weinstock M. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol 2003;184:1043–1052
16. McLenachan S, Chen X, McMennan PG, Rakoczy EP. Absence of clinical correlates of diabetic retinopathy in the Ins2Akita retina. Clin Experiment Ophthalmol 2013:41:582–592
17. Pires I, Santos AR, Nunes S, Lobo C. Macular thickness measured by stratus optical coherence tomography in patients with diabetes type 2 and mild non-proliferative retinopathy without clinical evidence of macular edema. Ophthalmologica 2013:229:181–186
18. Zhao XF, Wan J, Powell C, Ramachandran R, Myers MG Jr, Goldman D. Leptin and IL-6 family cytokines synergize to stimulate Müller glia reprogramming and retina regeneration. Cell Reports 2014;9:272–284
19. Towler DA, Bidder M, Lathit T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998;273:30427–30434
20. Martin PM, Roon P, Van Ellis TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004;45:3330–3336
21. Elhabashy SA, Elbarbarny NS, Nageb KM, Mohammed MM. Can optical coherence tomography predict early retinal microvascular pathology in type 1 diabetic adolescents without minimal diabetic retinopathy? A single-centre study. J Pediatr Endocrinol Metab 2015;28:139–146
22. Vujosevic S, Mithen E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Müller cells alterations. J Diabetes Res 2013;2013:90508
23. Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech 2012;5:444–456
24. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown potentials predict progression of diabetic retinopathy. Preliminary report. Arch Ophthalmol 1984;102:1307–1311
on a high-fat diet. BMC Ophthalmol 2013;13:14
39. Mancini JE, Ortiz G, Croxatto JO, Gallo JE. Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat diet. BMC Ophthalmol 2013;13:14
40. Marçal AC, Leonelli M, Fiamoncini J, et al. Diet-induced obesity impairs AKT signalling in the retina and causes retinal degeneration. Cell Biochem Funct 2013;31:65–74
41. Noda K, Nakao S, Zandi S, Sun D, Hayes KC, Hafezi-Moghadam A. Retinopathy in a novel model of metabolic syndrome and type 2 diabetes: new insight on the inflammatory paradigm. FASEB J 2014;28:2038–2046
42. Asi H, Perlman I. Relationships between the electroretinogram a-wave, b-wave and oscillatory potentials and their application to clinical diagnosis. Doc Ophthalmol 1992;79:125–139
43. Han Y, Bearse MA Jr, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci 2004;45:948–954
44. Palmowski AM, Sutter EE, Bearse MA Jr, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci 1997;38:2586–2596
45. Layton CJ, Safa R, Osborne NN. Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefes Arch Clin Exp Ophthalmol 2007;245:1335–1345
46. Sims MH. Partial masking of the canine electroretinogram by oscillatory potentials. The problem of frequency bandwidth. J Vet Intern Med 1990;4:40–42
47. Heynen H, Wachtmeister L, van Norren D. Origin of the oscillatory potentials in the primate retina. Vision Res 1985;25:1365–1373
48. Wachtmeister L, Dowling JE. The oscillatory potentials of the mudpuppy retina. Invest Ophthalmol Vis Sci 1978;17:1176–1188
49. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature 2010;468:232–243
50. Cerani A, Tetreault N, Menard C, et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab 2013;18:505–518
51. Mishra A, Newman EA. Inhibition of inducible nitric oxide synthase reverses the loss of functional hyperemia in diabetic retinopathy. Glia 2010;58:1996–2004
52. Okabe K, Kobayashi S, Yamada T, et al. Neurons limit angiogenesis by titrating VEGF in retina. Cell 2014;159:584–596
53. Sun A, Glis D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011;12:408–415
54. Moon JS, Lee S, Park MA, et al. UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis. J Clin Invest 2015;125:665–680